BREAKTRHOUGH BIOTECHNOLOGIES: CAN THE FDA KEEP UP WITH THE SPEED OF SCIENCE?

DSpace/Manakin Repository

. . . . . .

Title:	BREAKTRHOUGH BIOTECHNOLOGIES: CAN THE FDA KEEP UP WITH THE SPEED OF SCIENCE?
Author:	Hong, Kristy
Citation:	BREAKTRHOUGH BIOTECHNOLOGIES: CAN THE FDA KEEP UP WITH THE SPEED OF SCIENCE? (2004 Third Year Paper)
Full Text & Related Files:	Hong.pdf (255.3Kb; PDF) Hong.rtf (244.2Kb; RTF file) Hong.html (195.3Kb; HTML)
Abstract:	Biotechnology advances have the potential to dramatically change the practice of medicine. Currently research is underway to find cures for diseases that were before untreatable, and many biotechnology products are already on the market improving the drugs and devices we use today. However, one important factor to ensure that the pace of biotechnology goes on unhindered is proper regulation. As the guardian of public health, the Food and Drug Administration has struggled to meet the demands of the rapidly growing field. In particular, the FDA has recognized three potential breakthrough areas of biotechnology that may need regulatory reform: cell and gene therapy, pharmacogenetics / pharmacogenomics, and novel drug delivery. This paper will examine the current state of these three technologies and the regulatory landscape surrounding them.
Terms of Use:	This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page:	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8889444